We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Sage Therapeutics (SAGE) Stock is Soaring 40% Today
Read MoreHide Full Article
On Tuesday, shares of biopharmaceutical company Sage Therapeutics Inc. (SAGE - Free Report) are sparing, up around 40% in afternoon trading after the company’s treatment for severe postpartum depression showed positive results in a phase 2 study.
Postpartum depression is a mood disorder that includes extreme sadness, anxiety, and exhaustion, making it hard for new mothers to care for themselves or others. According to the American Psychological Association, there are no approved drugs for postpartum depression currently on the market. Postpartum depression affects up to one in seven women who give birth.
Sage said that data was compiled on 21 patients. 10 patients were given the company’s drug, SAGE-547, while 11 others received a placebo. The company said that 60 hours after treatment, the patients who received SAGE-547 saw significant reduction in symptoms, in comparison with the women who received the placebo, on a standard depression scale used in clinical research. The difference in treatment started at 24 hours, lasting through to the end of the 30-day study.
In a press release, trial investigator Samantha Meltzer-Brody said that "This is potentially one of the most important clinical findings in the pharmacologic treatment of postpartum depression to date.”
Sage also said that the study adjusted the dosage of SAGE-547 based on body weight, and all patients tolerated the drug fairly well. Thanks to the positive results, the company has initiated an expansion of this phase 2 study in order to determine the optimal dosage of SAGE-547 in treating postpartum depression; enrollment is expected to begin by the end of next year.
Sage Therapeutics sits at a #3 (Hold) on the Zacks Rank.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Sage Therapeutics (SAGE) Stock is Soaring 40% Today
On Tuesday, shares of biopharmaceutical company Sage Therapeutics Inc. (SAGE - Free Report) are sparing, up around 40% in afternoon trading after the company’s treatment for severe postpartum depression showed positive results in a phase 2 study.
Postpartum depression is a mood disorder that includes extreme sadness, anxiety, and exhaustion, making it hard for new mothers to care for themselves or others. According to the American Psychological Association, there are no approved drugs for postpartum depression currently on the market. Postpartum depression affects up to one in seven women who give birth.
Sage said that data was compiled on 21 patients. 10 patients were given the company’s drug, SAGE-547, while 11 others received a placebo. The company said that 60 hours after treatment, the patients who received SAGE-547 saw significant reduction in symptoms, in comparison with the women who received the placebo, on a standard depression scale used in clinical research. The difference in treatment started at 24 hours, lasting through to the end of the 30-day study.
In a press release, trial investigator Samantha Meltzer-Brody said that "This is potentially one of the most important clinical findings in the pharmacologic treatment of postpartum depression to date.”
Sage also said that the study adjusted the dosage of SAGE-547 based on body weight, and all patients tolerated the drug fairly well. Thanks to the positive results, the company has initiated an expansion of this phase 2 study in order to determine the optimal dosage of SAGE-547 in treating postpartum depression; enrollment is expected to begin by the end of next year.
Sage Therapeutics sits at a #3 (Hold) on the Zacks Rank.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>